N8-GP (Hemophilia A and B):市場予測と分析(~2022)...市場調査レポートについてご紹介

【英文タイトル】N8-GP (Hemophilia A and B) - Forecast and Market Analysis to 2022

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼
N8-GP (Hemophilia A and B):市場予測と分析(~2022) (Code:GDATA403162943)

【レポートの概要(一部)】

N8-GP (Hemophilia A and B) – Forecast and Market Analysis to 2022

Summary

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Novo Nordisk’s long-lasting recombinant FVIII replacement therapy is currently in Phase III development. N8-GP is a pegylated version of Novoeight, Novo’s FVIII replacement therapy that received FDA approval in October 2013. On April 26, 2012, N8-GP was awarded EMA orphan status (EU/3/12/995).

Scope

– Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
– Detailed information on N8-GP including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
– Sales forecast for N8-GP for the top nine countries from 2012 to 2022._x000D_
– Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
– Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B_x000D_
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
– Make more informed business decisions from insightful and in-depth analysis of N8-GP performance_x000D_
– Obtain sales forecast for N8-GP from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China)

.....

【日本語概要(※自動翻訳出力)】

※以下は、Microsoft社の翻訳システムを使用した自動翻訳結果です。レイアウト崩れと不自然な日本語表現が多く表示されます。

。。。(後略)

【レポートの目次(一部)】

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 13
3.1.3 Prognosis and Quality of Life 15
3.2 Symptoms 17
3.2.1 Hemophilia A and B 17
3.2.2 Inhibitors 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Hemophilia A and B Diagnosis 20
4.1.2 Hemophilia A and B Treatment 20
4.1.3 Inhibitors Diagnosis 22
4.1.4 Inhibitors Treatment 22
5 Competitive Assessment 24
5.1 Overview 24
5.2 Strategic Competitive Assessment 25
6 Opportunity and Unmet Need 29
6.1 Overview 29
6.2 Opportunities Analysis 30
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 30
6.2.2 Lower-Cost Recombinant Replacement Therapies 31
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 32
6.2.4 More Convenient Drug Administration 32
6.2.5 Oral Formulation of Recombinant Replacement Therapies 33
6.3 Unmet Needs Gap Analysis 34
6.3.1 Long-Acting FVIII Replacement Therapies 34
6.3.2 Gene Therapy Treatments for Hemophilia A and B 34
7 Pipeline Assessment 35
7.1 Overview 35
7.2 Promising Drugs in Clinical Development – Hemophilia A 35
7.3 Promising Drugs in Clinical Development – Hemophilia B 37
7.4 Promising Drugs in Clinical Development – Hemophilia A and B Patients with Inhibitors 39
8 N8-GP (NN7088) 40
8.1 Overview 40
8.2 Efficacy 41
8.3 Safety 41
8.4 Dosing and Formulation 41
8.5 Potential Clinical Positioning 41
8.6 Potential Commercial Positioning 42
8.7 Pricing and Reimbursement 43
8.8 SWOT Analysis 43
8.9 Forecast 43
9 Appendix 45
9.1 Bibliography 45
9.2 Abbreviations 48
9.3 Methodology 50
9.4 Forecasting Methodology 50
9.4.1 Diagnosed Hemophilia Patients 51
9.4.2 Percent Drug-Treated Patients 51
9.4.3 General Pricing Assumptions 52
9.4.4 Pricing of Pipeline Agents 52
9.5 Physicians and Specialists Included in this Study 53
9.6 About the Authors 55
9.6.1 Authors 55
9.6.2 Global Head of Healthcare 56
9.7 About GlobalData 57
9.8 Disclaimer 57

.....

【日本語目次(※自動翻訳出力)】

※以下は、Microsoft社の翻訳システムを使用した自動翻訳結果です。レイアウト崩れと不自然な日本語表現が多く表示されます。

。。。(後略)

【レポート販売概要】

■ タイトル:N8-GP (Hemophilia A and B):市場予測と分析(~2022)
■ 英文:N8-GP (Hemophilia A and B) - Forecast and Market Analysis to 2022
■ 発行日:2013年11月30日
■ 調査会社:GlobalData
■ 商品コード:GDATA403162943
■ 調査対象地域:グローバル

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼
N8-GP (Hemophilia A and B):市場予測と分析(~2022) (N8-GP (Hemophilia A and B) - Forecast and Market Analysis to 2022 / GDATA403162943)

※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。